Namibia - English - Namibia Medicines Regulatory Council

teva pharmaceuticals (pty) ltd - fludarabine phosphate - concentrate for solution for injection - each 2 ml vial contains; fludarabine phosphate 50,0 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - fludarabine phosphate 25 mg/ml;   - powder for injection - 50 mg/2ml - active: fludarabine phosphate 25 mg/ml   excipient: mannitol sodium hydroxide

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fludarabine phosphate 10mg - film coated tablet - 10 mg - active: fludarabine phosphate 10mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose purified talc titanium dioxide - the treatment of b-cell chronic lympocytic leukaemia.

Ireland - English - HPRA (Health Products Regulatory Authority)

genzyme europe b.v. - fludarabine phosphate - film-coated tablet - 10 milligram(s) - purine analogues; fludarabine

Ireland - English - HPRA (Health Products Regulatory Authority)

genzyme europe b.v. - fludarabine phosphate - powder for solution for injection/infusion - 50 milligram(s) - purine analogues; fludarabine

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - fludarabine phosphate -

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ebewe pharma - fludarabine phosphate - solution for injection - 25 mg/ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية الصباغ - sabbagh drug store - fludarabine phosphate 25 mg/ml - 25 mg/ml

Israel - English - Ministry of Health

salomon,levin & elstein ltd - fludarabine phosphate 50 mg / 2 ml - concentrate for solution for injection / infusion - fludarabine - palliative treatment of patients with cll refractory to other therapy. treatment of less malignant non-hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. fludarabine teva is indicated for the initial treatment of patients with b- cell chronic lymphocytic leukaemia (cll) or after first line therapy, in patients with sufficient bone marrow reserves.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fludarabine phosphate -